Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... MNKD ) announced today that it has agreed to ... in registered direct offerings to,Alfred E. Mann, its principal ... Directors, and to two groups of investors,including accounts managed ... 15,940,489 shares were sold to Mr. Mann at a ...
... Reba McEntire, NFL Players Among Stars Participating in, PSA Campaign Created ... Renowned Photographer Mary Ellen Mark and Cancer Vixen ... Author Marisa Acocella Marchetto, Partnership with ... of Life & Dating, Starring Ricki Lake and Holly Robinson, Peete, ...
... Oct. 2 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and,commercial development of technologies targeting the chronic inflammation,underlying ... after the close of the North American financial ... and audio web cast will also,be conducted on ...
Cached Biology Technology:MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 2MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock 3Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Television's 13th Annual Multi-Platform 'Stop Breast Cancer For Life' Campaign 2Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Television's 13th Annual Multi-Platform 'Stop Breast Cancer For Life' Campaign 3Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Television's 13th Annual Multi-Platform 'Stop Breast Cancer For Life' Campaign 4Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Television's 13th Annual Multi-Platform 'Stop Breast Cancer For Life' Campaign 5Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Television's 13th Annual Multi-Platform 'Stop Breast Cancer For Life' Campaign 6Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... The human genome has been decoded. Of all the puzzles ... genome provides the blueprint for various proteins, the building blocks ... play? Which proteins control cell division in a healthy body, ... which cells incessantly subdivide and control over proteins gets out ...
... genes in the human genome is what makes each human ... researchers at the Johns Hopkins Bloomberg School of Public Health, ... of Mental Health found that many gene expression changes that ... of fetal expression changes are also seen again much later ...
... German . The ability to dream is ... and emotions that we experience so intensively when we dream form ... not been possible to measure dream content. Max Planck scientists working ... for the first time, in analysing the activity of the brain ...
Cached Biology News:Cell cultures from a machine 2Scientists chart gene expression in the brain across lifespan 2Scientists measure dream content for the first time 2
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
Sheep Serum US Origin...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: